Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (Nasdaq: IART) will exhibit at the Congress of Neurological Surgeons Annual Meeting in Los Angeles from October 11–15, 2025. The company will showcase neurosurgical devices including Durepair Dura Regeneration Matrix and Mayfield Ghost Base Unit, Post, plus CereLink ICP Monitoring System, CUSA Clarity Tissue Ablation System, Aurora Surgiscope System, and Certas Plus Programmable Valve. Integra will be at booth #713 to engage neurosurgeons and demonstrate product features aimed at improving surgical visualization and dural repair.
Integra LifeSciences (Nasdaq:IART) has appointed Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings over 20 years of surgical and leadership experience from major MedTech companies, including Siemens Healthineers and Johnson & Johnson.
In his new role, Dr. Turner will lead worldwide medical affairs and clinical development activities, while maintaining his clinical practice. His extensive background includes serving as chief medical officer at Siemens Endovascular Robotics and program director at the Medical University of South Carolina. Dr. Turner has authored over 150 peer-reviewed publications and participated in more than 70 research studies.
Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, announced its executive leadership participation in two upcoming healthcare investor conferences. CEO Mojdeh Poul and CFO Lea Knight will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ET, and the Morgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET.
Investors can access live webcasts of both presentations through Integra LifeSciences' investor relations website under the Events & Presentations section.
Integra LifeSciences (NASDAQ: IART) reported mixed Q2 2025 financial results with revenues of $415.6 million, showing a slight decline of 0.6% reported and 1.4% organic year-over-year. The company posted a significant GAAP net loss of $(6.31) per share, primarily due to a $511 million goodwill impairment charge, compared to $(0.16) in the prior year.
The Codman Specialty Surgical segment (~70% of revenues) reached $304.0 million, growing 0.7% reported, while Tissue Technologies (~30%) declined 4.1% to $111.6 million. The company updated its full-year 2025 revenue guidance to $1.655-1.680 billion and maintained adjusted EPS guidance of $2.19-2.29.
Integra is implementing a Compliance Master Plan and has completed all manufacturing site assessments, while launching profitability initiatives to drive efficiency gains over the next 12-18 months.
Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, has scheduled its second quarter 2025 financial results release for Thursday, July 31, 2025, before market open. The company will host a conference call at 8:30 a.m. ET the same day to discuss the results.
Investors can access the live webcast through the company's investor relations website at investor.integralife.com. Those wishing to participate in the call must register to receive dial-in details and an individual pin. A replay of the webcast will be available on the company's website after the call.
Integra LifeSciences (Nasdaq: IART) has announced the enrollment of its first patient in the Acclarent AERA Pediatric Registry, a significant milestone in pediatric Eustachian tube dysfunction (ETD) treatment research. The registry will evaluate the real-world use of the AERA Eustachian Tube Balloon Dilation System in children.
The multi-center observational study aims to enroll up to 300 pediatric patients across 20 U.S. sites. Dr. Prasad Thottam at Michigan Pediatric ENT Associates enrolled the first patient. The registry will track safety and efficacy outcomes, with the primary endpoint focusing on failure-free status following the procedure. Secondary endpoints include various clinical measurements and patient-reported outcomes.
Integra LifeSciences (NASDAQ: IART), a global medical technology company, has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET the same day to discuss the results.
Investors can access a live webcast through the company's investor relations website at investor.integralife.com. Those wishing to participate in the call must register to receive dial-in details and an individual pin. Participants are advised to join 10 minutes before the event starts. A replay of the webcast will be available on the company's investor section after the call.
Integra LifeSciences (NASDAQ: IART) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. CEO Mojdeh Poul and CFO Lea Knight will deliver a presentation on March 17, 2025, at 10:00am ET.
The global medical technology company will provide a live webcast of the presentation, which will be accessible through their investor relations website at investor.integralife.com/events-and-presentations.
Integra LifeSciences (NASDAQ: IART) reported Q4 2024 revenues of $442.6 million, an 11.5% increase (3.5% organic growth) compared to Q4 2023. Q4 adjusted EPS was $0.97, up from $0.89 in the prior year period.
For full-year 2024, revenues reached $1,610.5 million, representing a 4.5% increase on a reported basis but a 1.3% decrease organically compared to 2023. Full-year adjusted EPS was $2.56, down from $3.10 in 2023.
The company's Codman Specialty Surgical segment (71% of revenues) grew 15.8% on a reported basis and 4.1% organically in Q4, while Tissue Technologies (29% of revenues) increased 2.1% both on a reported and organic basis.
For 2025, Integra expects revenues between $1,650-$1,715 million (2.4-6.5% reported growth) and adjusted EPS of $2.41-$2.51. Q1 2025 revenue is projected at $375-$385 million with adjusted EPS of $0.40-$0.45.